IMMUNOGENICITY OF A RECOMBINANT HEPATITIS-B VACCINE IN HEMODIALYSIS-PATIENTS - A 2-YEAR FOLLOW-UP

被引：24

作者：

DOCCI, D ^{[1
]}

CIPOLLONI, PA ^{[1
]}

MENGOZZI, S ^{[1
]}

BALDRATI, L ^{[1
]}

CAPPONCINI, C ^{[1
]}

FELETTI, C ^{[1
]}

机构：

[1] OSPED GEN PROVINCIALE M BUFALINI,ANAL LAB,CESENA,ITALY

来源：

NEPHRON | 1992年 / 61卷 / 03期

关键词：

HEMODIALYSIS; HEPATITIS-B VACCINATION; RECOMBINANT HEPATITIS-B VACCINE;

D O I：

10.1159/000186939

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The immunogenicity of a recombinant hepatitis B vaccine was evaluated in 35 hemodialysis patients who received a standard dose (20-mu-g) of the vaccine at 0, 1, 2 and 6 months. After the full vaccination course (month 7), 60% (21/35) of the patients had seroconverted (anti-HBs titer greater-than-or-equal-to 10 mIU/ml). The duration of protection lasted up to 18 months after the start of vaccination in 85.7% (18/21) of the responders. At that time, an additional dose was given to all the patients: 1-2 months later, the overall immunization rate had increased to 65.7% (23/35), lastly, in month 24 (i.e., 6 months after the booster dose), 62.5% (15/24) of the patients available for evaluation were still maintaining protective levels of anti-HBs antibodies. Comparable results had previously been obtained in 21 well-matched patients on our dialysis program who were vaccinated with a plasma-derived vaccine according to the recommended schedule.

引用

页码：352 / 353

页数：2